Displaying drugs 15026 - 15050 of 15772 in total
Dirloctocogene samoparvovec
Investigational
Cotoretigene toliparvovec
Investigational
Entacingene turiparvovec
Investigational
Fordadistrogene movaparvovec
Investigational
Pariglasgene brecaparvovec
Investigational
Patidistrogene bexoparvovec
Investigational
Domofenogene zalfaparvovec
Domofenogene zalfaparvovec, formerly known as BMN-307, is an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy developed by BioMarin Pharmaceutical.
Experimental
Ifezuntirgene inilparvovec
Experimental
Ixoberogene soroparvovec
Investigational
Zaftuclenegene piruparvovec
Experimental
Human Laminin-111
Investigational
Recombinant methionyl brain-derived neurotrophic factor
Investigational
Tegoprubart
Investigational
ABO-202
Investigational
Spheramine
Investigational
BBP-812
Investigational
TSHA-120
Investigational
TVN-102
Investigational
Vesleteplirsen
Investigational
CV-MG01
Investigational
AT-GTX-502
AT-GTX-502 is an experimental, one-time gene therapy that uses AAV9 to deliver a functional copy of CLN3.
Investigational
BMN-045
Experimental
Withdrawn
AMZ002
AMZ002 is a sterile injectable hormone developed as a purified synthetic polypeptide alternative to current FDA-approved epileptic seizure treatments.
Investigational
AVI-014
AVI-014 is a glycosylated, recombinant human granulocyte colony-stimulating factor (G-CSF).
Investigational
Displaying drugs 15026 - 15050 of 15772 in total